Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Haloperidol for the treatment of delirium in critically ill patients: a systematic review with meta-analysis and Trial Sequential Analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Inadequate emergence after non-cardiac surgery-A prospective observational study in 1000 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Time to onset of gastrointestinal bleeding in the SUP-ICU trial: a preplanned substudy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Heterogeneity of treatment effect of stress ulcer prophylaxis in ICU patients: A secondary analysis protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pantoprazole in ICU patients at risk for gastrointestinal bleeding-1-year mortality in the SUP-ICU trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Storage time of red blood cells among ICU patients with septic shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Haloperidol is the most frequently used drug to treat delirium in the critically ill patients. Yet, no systematic review has focussed on the effects of haloperidol in critically ill patients with delirium.

METHODS: We conducted a systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials (RCTs) assessing the effects of haloperidol versus any intervention on all-cause mortality, serious adverse reactions/events, days alive without delirium, health-related quality of life (HRQoL), cognitive function and delirium severity in critically ill patients with delirium. We also report on QTc prolongation, delirium resolution and extrapyramidal symptoms.

RESULTS: We included 8 RCTs with 11 comparisons (n=951). We adjudicated one trial as having overall low risk of bias. Three trials used rescue haloperidol; excluding these, we did not find an effect of haloperidol versus control on all-cause mortality (RR 1.01; 95% CI 0.33-3.06; I2 =0%; 112 participants; 3 trials; 4 comparisons; very low certainty) or delirium severity (SMD -0.15; 95% CI -0.61-0.30; I2 =27%; 134 participants; 3 trials; 4 comparisons; very low certainty). No trials reported adequately on serious adverse reactions/events. Only one trial reported on days alive without delirium, cognitive function and QTc prolongation, and no trials reported on HRQoL. Sensitivity analyses, including trials using rescue haloperidol, did not change the results.

CONCLUSIONS: The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality, and inconclusive. We therefore have no certainty regarding any beneficial, harmful or neutral effects of haloperidol in these patients.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
ISSN0001-5172
DOI
StatusE-pub ahead of print - 29 okt. 2019

Bibliografisk note

© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 58261819